Using AI and DNA technology to find new treatments for substance use disorders
Synergy between Artificial Intelligence and DNA-Encoded Library technologies to Identify Polypharmacological Therapeutics for Substance Use Disorders
This study is exploring how to use advanced technology to find new treatments for people struggling with substance use disorders, aiming to help reduce cravings and withdrawal symptoms while also supporting emotional well-being.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jillion Therapeutics INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11142938 on NIH RePORTER |
What this research studies
This research aims to combine artificial intelligence with a unique DNA-encoded library to discover new compounds that can treat substance use disorders (SUDs). By targeting multiple neurotransmitter systems, including opioid and dopamine pathways, the project seeks to develop therapies that can alleviate cravings and withdrawal symptoms while also addressing emotional challenges associated with SUDs. The approach involves identifying molecules that can interact with specific receptors in the brain to restore balance and improve overall brain function. Patients may benefit from innovative treatments that are tailored to their specific needs.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing substance use disorders.
Not a fit: Patients who are not struggling with substance use disorders or who are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective therapies for individuals struggling with substance use disorders.
How similar studies have performed: While the combination of AI and DNA-encoded libraries is a novel approach, similar research has shown promise in drug discovery and treatment development.
Where this research is happening
New York, United States
- Jillion Therapeutics INC. — New York, United States (Active)
Researchers
- Principal investigator: Flajolet, Marc — Jillion Therapeutics INC.
- Study coordinator: Flajolet, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.